Abbott Laboratories (ABT) is back in focus after winning European clearance for its Libre Duo glucose ketone sensors and securing approval for its Ultreon 3.0 AI coronary imaging software.

Despite the fresh regulatory wins for Libre Duo and Ultreon 3.0, Abbott Laboratories’ share price is down 30.5% year to date and the 1 year total shareholder return has declined 33.7%. This suggests recent momentum has faded even as product news keeps coming.

If this kind of healthcare AI progress has your attention, it may be worth seeing what else is on the move by checking out 35 healthcare AI stocks

With the share price down sharply this year yet trading about 36% below one estimate of intrinsic value and 37% below the average analyst target, you have to ask: is this a reset buying opportunity, or is the market already discounting future growth?

Most Popular Narrative: 24.2% Undervalued

At a last close of $86.30 compared with a narrative fair value of $113.88, Abbott Laboratories is framed as materially undervalued by one detailed thesis.

Abbott Laboratories is a compelling growth investment with defensive qualities, supported by its market leadership, innovation-driven strategy, and diversified portfolio. While its premium valuation may limit near-term upside, the company’s strong fundamentals, exposure to high-growth markets, and commitment to shareholder returns make it a solid choice for investors with a medium to long-term horizon.

Want to see what is driving that valuation gap? The narrative leans heavily on sustained earnings growth, richer profit margins, and a future market multiple that assumes investors will keep paying up.

Result: Fair Value of $113.88 (UNDERVALUED)

However, this hinges on assumptions about earnings growth and valuation multiples, which could be challenged by tougher regulation or faster competitive pressure in key device and diagnostic markets.

Next Steps

With sentiment clearly split between concern and optimism, this is the moment to check the underlying data yourself and decide where you stand by weighing up the 5 key rewards and 2 important warning signs

Looking for more investment ideas?

If you are serious about sharpening your watchlist, do not stop at a single stock when there are so many other opportunities worth scanning with data on your side.

• Target potential mispricings by scanning companies that screen as quality yet undervalued using the 46 high quality undervalued stocks.
• Prioritise resilience by focusing on businesses that pass tough balance sheet and fundamentals checks via the solid balance sheet and fundamentals stocks screener (46 results).
• Get ahead of the crowd by zeroing in on lesser known stocks with strong fundamentals using the screener containing 22 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.